Cryptococcus (IDSA 2010): Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[https://doi.org/10.1086/649858 Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update] |
|||
<blockquote>[https://doi.org/10.1086/649858 Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update] |
|||
</blockquote> |
|||
== Meningoencephalitis == |
== Meningoencephalitis == |
||
| Line 23: | Line 21: | ||
== Special Populations == |
== Special Populations == |
||
[[Category:IDSA guidelines]] |
|||
[[Category:CNS infections]] |
|||
[[Category:Yeasts]] |
|||
Latest revision as of 19:33, 15 August 2019
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update
Meningoencephalitis
HIV-infected
- Induction: AmBd 0.7-1 mg/kg/d IV plus flucytosine 100 mg/kg/d po split QID for at least 2 weeks
- Can use liposomal AmB 3–4 mg/kg/d IV or ABLC 5 mg/kg/d IV
- Can continue for 4-6 weeks if high fungal burden or failure to respond
- Can replace flucytosine with fluconazole 800-1200 mg daily for minimum of 8 weeks if needed
- Consolidation: fluconazole 400 mg daily for at least 8 weeks
- If high
